[Mounjaro (tirzepatide)] and [Ozempic (semaglutide)] can effectively reduce the "risk of cancer"!
The latest important study published at the International Digestive Disease Week (DDW) in Chicago: Obese patients who receive GLP-1 receptor agonists (such as: Ozempic (semaglutide)) or dual GLP-1/GIP receptor agonists (such as: Mounjaro (tirzepatide)) have significantly lower overall cancer risks and skin cancer risks than those who do not receive treatment.
The results of this study show that in addition to a lower incidence of cancer in those who received the treatment, the risk of skin cancer was reduced by about 25%. This means that in the past, people thought obesity was just a "weight problem", but now medical science has further confirmed that obesity is actually closely related to common diseases such as chronic inflammation, hormonal imbalance, insulin resistance, sleep quality, neurological and metabolic regulation... etc.! The reason why GLP-1 drugs have attracted attention is not only because patients obviously "eat less" after being injected or taken, but also because the brain's appetite control, metabolic regulation and systemic inflammatory response are significantly improved.
Of course, the current research results are "cancer risk reduction" and do not mean that GLP-1 is an "anti-cancer drug". What is really important is to return to the adjustment of life and body rhythm. As the old saying goes: Out-of-control weight mostly comes from an out-of-control brain!
